SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001347178-21-000015
Filing Date
2021-05-06
Accepted
2021-05-06 07:01:47
Documents
75
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q vnda-20210331.htm   iXBRL 10-Q 1033372
2 EX-31.1 vndaex311331202110q.htm EX-31.1 10530
3 EX-31.2 vndaex312331202110q.htm EX-31.2 10203
4 EX-32.1 vndaex321331202110q.htm EX-32.1 6714
  Complete submission text file 0001347178-21-000015.txt   5353841

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vnda-20210331.xsd EX-101.SCH 46127
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT vnda-20210331_cal.xml EX-101.CAL 82475
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT vnda-20210331_def.xml EX-101.DEF 199025
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vnda-20210331_lab.xml EX-101.LAB 505992
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vnda-20210331_pre.xml EX-101.PRE 342383
10 EXTRACTED XBRL INSTANCE DOCUMENT vnda-20210331_htm.xml XML 787953
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34186 | Film No.: 21895709
SIC: 2834 Pharmaceutical Preparations